Botox for Sweaty Armpits: Evidence and Risks

Botox reduced underarm sweat more than placebo in a 320-person trial#

Botox is an onabotulinumtoxinA injection approved in the United States for severe primary axillary hyperhidrosis in adults when topical agents have not managed the sweating adequately.[2] Its evidence is specific: injections are placed intradermally in the affected underarm area by a qualified clinician. The label does not establish safety and effectiveness for treating hyperhidrosis in other body areas.[2]

In a multicenter randomized trial, 320 adults with bilateral primary axillary hyperhidrosis received 50 units of botulinum toxin A per axilla or placebo. A responder had at least a 50% reduction in axillary sweating. At week 4, 94% of the botulinum toxin group and 36% of the placebo group were responders; at week 16, the rates were 82% and 21%, respectively.[1]

These results support a substantial temporary treatment effect through 4 months. They do not establish a permanent cure or predict the exact duration for an individual patient.

The FDA label places Botox after inadequate topical treatment#

The current label indicates Botox for severe primary axillary hyperhidrosis that is inadequately managed with topical agents.[2] That wording matters. It does not present injections as a casual first step for any amount of underarm moisture, and it does not replace evaluation for secondary causes of excessive sweating.

The label describes 50 units per axilla distributed across multiple intradermal injection sites and says repeat treatment should occur when the prior clinical effect diminishes.[2] Those are labeling facts, not instructions for self-treatment. Botox must be prepared and administered by a trained professional, and product units are not interchangeable with units from other botulinum toxin products.

Benefit persisted through 16 weeks, with longer response in other label data#

The 320-person study provides controlled evidence through week 16.[1] A separate FDA-reviewed study of 322 adults found a median response duration of 201 days after the first treatment, with similar median duration after a second treatment.[2] Because study designs and response definitions differ, those figures should not be blended into one guaranteed duration for an individual patient.

The accurate expectation is that treatment is temporary and repeat injections may be needed. Duration varies, and the label ties retreatment to return of the clinical effect rather than a fixed calendar promise.

Adverse events and funding belong beside the efficacy result#

The pivotal 320-person study was supported by Allergan. Both authors reported financial ties to the company, and one reported owning Allergan shares.[1] Treatment-related adverse events occurred in 11% of the botulinum toxin group and 5% of the placebo group; increased sweating outside the treated underarm area was among the reported events. The difference in overall treatment-related adverse-event rates was not statistically significant.[1] The 16-week follow-up limits what that trial can establish about repeated long-term treatment.

The current Botox label carries a boxed warning that toxin effects may spread beyond the injection site and cause serious symptoms. It also lists contraindications, drug interactions, and condition-specific precautions that require professional screening.[2] This page cannot determine whether the expected benefit outweighs those risks for a particular person.

Botox is not the same treatment as iontophoresis or Qbrexza#

Botox prevents acetylcholine release from nerve endings around treated sweat glands.[2] Qbrexza blocks acetylcholine receptors with a daily prescription cloth, while iontophoresis uses repeated electrical-current sessions. Separate trials support each modality for particular body sites, but they do not create a universal ranking.

For the prescription-cloth evidence, see Qbrexza trial results and safety. For hands and feet, see iontophoresis machines: evidence and limits.

Bottom line#

Randomized evidence supports Botox for severe primary underarm hyperhidrosis: in a 320-person trial, sweat reduction and responder rates were substantially better than placebo through 16 weeks.[1] The treatment is temporary, prescription-only, professionally administered, and accompanied by adverse-event and boxed-warning considerations.[2]

This article is educational and does not diagnose excessive sweating, recommend injections, or replace evaluation by a qualified clinician.

References#

1. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323(7313):596-599. PubMed PMID 11557704 and DOI 10.1136/bmj.323.7313.596

2. U.S. National Library of Medicine. Botox (onabotulinumtoxinA) prescribing information, revised February 2026. DailyMed label